<DOC>
	<DOCNO>NCT01738074</DOCNO>
	<brief_summary>Assessment evaluation rotavirus gastroenteritis prevention effect severe rotavirus diarrhea reduce effectiveness human body , inoculate trivalent rotavirus genetic reassortment vaccine .</brief_summary>
	<brief_title>Phase Three Clinical Trials Trivalent Rotavirus Genetic Reassortment Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>6 13 week age healthy baby ; Guardian volunteer participate study sign inform consent ; use thermometer require ability fill diary table ; Subjects guardian abide requirement clinical research scheme ; The past vaccinate rotavirus vaccine ; Normal term eutocia , birth weight standard ; Axillary temperature 37.0 â„ƒ less . With allergy , convulsion , epilepsy , encephalopathy spirit history family history ; Be allergy ingredient vaccine ; Known immunology function damage low person ; Immunosuppressant therapy Accepter ; Suffering congenital malformation developmental disorder ; Known suspect also suffer disease include : digestive system disease , respiratory system disease , acute infection , mother I HIV infection , cardiovascular disease , malignant tumor treatment , skin disease ; Inoculation vaccine within 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>13 Weeks</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>rotavirus</keyword>
	<keyword>trivalent genetic reassortment vaccine</keyword>
	<keyword>Phase three clinical trial</keyword>
</DOC>